1 min read

Technology Landscape and Challenges of High Throughput vs. POC Diagnostics

As the world is beginning to understand, SARS-CoV-2 poses several unique challenges. Asymptomatic and infected individuals are highly contagious and present unprecedented viral transmissibility. As countries and markets try to fully understand the economic impact of the pandemic, the value of a rapid diagnostic test for a rapidly spreading virus has never been more clearly demonstrated. The IATA projects that worldwide, the airline industry alone will see 2020 full year passenger revenues plummet by $252 billion, or 44% below 2019’s figure.

In the absence of a vaccine or a treatment for SARS-CoV-2, the only strategy against the spread of the novel coronavirus is to “detect and isolate.” While the number of new cases continues to rise throughout the world, there is a clear escalation of technologies and products to detect SARS-CoV-2. Given the nature and scale of the pandemic, we expect diagnostic trends such as access to point of care, connected systems, and innovative sample collection techniques to accelerate the market landscape.

Exploring the Assay Development Pipeline for In-Vitro Diagnostics (IVDs)

Exploring the Assay Development Pipeline for In-Vitro Diagnostics (IVDs)

Establishing a Strong Assay Foundation

Read More
Webinar – 2024 IVDR Sprint Series: Usability and Human Factors: Cornerstones of Near Patient Testing – Insights and Perspectives from a Notified Body

Webinar – 2024 IVDR Sprint Series: Usability and Human Factors: Cornerstones of Near Patient Testing – Insights and Perspectives from a Notified Body

Near-patient testing (NPT) devices face substantial challenges under the new IVDR, including: New Stringent Regulatory Constraints due to IVDR

Read More

4 min read

Is China a 300 Million or 1.4 Billion Healthcare Population Market?

A reflection on the 2019 capability development progress report of the county hospitals in China The Veranex (formerly Boston Healthcare...

Read More